FDA Eyes Warning Label for Antidepressants During Pregnancy

The FDA is considering a black-box warning for antidepressant use during pregnancy, prompting debate among medical experts. While some studies suggest serotonin reuptake inhibitors (SSRIs) may pose risks to fetal development, leading to concerns about miscarriage, low birth weight, or organ effects, physicians emphasize that untreated maternal depression carries significantly higher risks for both parent and child.

 

The American College of Obstetricians and Gynecologists cautions that alarmist claims could discourage treatment, highlighting the importance of addressing maternal mental health during pregnancy and postpartum. Public health communicators may play a key role in balancing messaging about medication safety and mental health care access. Read more from The Hill here.